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INTRODUCTION
Peripheral T-cell lymphoma (PTCL) comprises a heterogeneous group of tumours derived from postthymic elements, including leukaemic/disseminated, nodal and extranodal diseases [1] [2] [3] . As orphan diseases [12-15% of all non-Hodgkin's lymphoma (NHL) in Western populations] [1] [2] [3] [4] , they include entities displaying a great variability in clinical, morphological, immunophenotypic, cytogenetic and molecular features. First described in 1985 [5] , anaplastic large cell lymphoma (ALCL) of either adults (2-8% of NHL) or children (15-30% of NHL) nowadays corresponds to specific subtypes of systemic PTCL [1] . The presence of anaplastic lymphoma kinase (ALK) gene fusions has provided the criteria for a new WHO classification, which contemplates a novel entity (i.e. ALCL ALKþ) and proposes a provisional one, including ALCL patients, who lack ALK translocations (i.e. ALCL ALKÀ).
Because of genetic, immunophenotypic and clinical differences, cutaneous ALCLs (cALCLs) are considered as a completely distinct subset distinct from its systemic counterpart. Systemic ALCLs share cytological, immunophenotypic and molecular features. However, ALKÀ ALCL patients, as a group, have poorer performance status, more often B symptoms [6] , and an overall survival (OS) rate of 36 versus 20% of peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) patients. This suggests that ALKÀ ALCL features oncogenic driving mechanisms biologically distinct from ALKþ ALCL. Whereas ALKþ ALCLs have a more favourable clinical course than ALKÀ cases [4] , a subset of ALKþ patients still display a more aggressive and refractory presentation [7] . It remains uncertain whether the molecular lesion(s) (i.e. ALK fusions) and/or other features determine the clinical course of ALCL patients. In fact, once ALCL patients are normalized by clinical parameters, ALKÀ and ALKþ ALCL patients within individual stages display analogous prognosis (failure-free survival and OS) [6] . Considering that ALKRR ALCLs have a less complex karyotype [8] [9] [10] [11] , it seems plausible that ALK fusions are critical actors and that tumour progression is due to somatic mutations (minimal deletions, activating somatic mutations and so on) disrupting the function of a limited set of genes. In contrast, the transformation of ALKÀ ALCL might require the consolidation/acquisition of many genetic defects that rapidly lead to systemic and more aggressive phenotype. This is suggested by their higher and heterogeneous karyotypes [8] [9] [10] [11] . Nonetheless, the driving lesion(s) of ALKÀ ALCL are still to be identified, and codrivers are lacking for both ALCL subgroups.
The lack of representative cell lines or animal models remains an impediment to our mechanistic characterization of mature T-cell lymphoma. Ultimately, this has jeopardized the design of successful therapies and the upgrade of clinical programmes, particularly in patients with poor outcome (ALKÀ ALCL and PTCL-NOS). The recognition of the tumourigenic defects of PTCL is expected to provide patient-specific 'molecular fingerprints' and thus more suitable tailored therapies.
ONCOGENIC SIGNALLING BY ANAPLASTIC LYMPHOMA KINASE FUSION PROTEINS
Chromosomal translocations of the ALK gene are documented in many ALCL patients, although the percentage of ALKþ ALCL varies as a result of the inclusion diagnostic criteria of ALKÀ ALCL cases. In the absence of strong classifier(s) (such as ALK), the distinction between ALKÀ ALCL, CD30 PTCL-NOS and some enteropathy-associated T-cell lymphoma represents a diagnostic challenge.
The ALK gene encodes a 210 kDa tyrosine kinase receptor (CD247) belonging to the insulin growth factor receptor superfamily. Its expression is largely limited to the nervous system during embryogenesis and to the focal areas of the adult brain [12] . Although the physiological role of ALK in mammals is unknown, it is involved in neuronal differentiation [13] and ALK activating mutations have been found in familial and sporadic neuroblastomas [14] .
The breakpoints of ALK chimeras invariably occur within the intron placed between the exons 19 and 20 (NM_004304.3). Thus, exons coding for the intracytoplasmic domain of ALK (exons [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] are then juxtaposed to different partners [15, 16] . Seventy to eighty per cent of ALKþ ALCL harbour the t(2;5)(p23;q35) translocation (NPM-ALK chimera). Alternative translocations of ALCL in which various partners are fused to ALK (i.e. TPM, TFG, ATIC, TSPYL2, MSN, KIAA1618, VCL, MYH9, KIFB5) have been described over the years [16] [17] [18] .
KEY POINTS
Anaplastic large cell lymphoma is a heterogeneous group of lymphomas that carry a restricted number of genetic defects, mainly involving the anaplastic lymphoma kinase (ALKþ ALCL) or less frequently displaying alternative translocations [t(2;x)(p23;x), t(6;7)(p25.3;q32.3) and inv(3)(q26q28) leading to TBL1XR1/TP63, and so on]. Nonetheless, specific lesions are still lacking for many ALCLs.
The precise relationship and origin of ALCL remain unclear. Although ALKþ and ALKÀ share a set of genes and similar phenotypes, they are considered distinct groups with unique clinical features. However, it is unknown whether clinical differences and responses to conventional therapies may simply be related to different clinical stages and/or unique genomic lesions.
Bioinformatics algorithms have identified several ALCL signalling classifiers demonstrating the preferential expression of a restricted number of pathways. The recognition of 'common hubs', which can be targeted by selective inhibitors, represents a viable strategy for future therapeutic protocols.
Taking advantage of in-vitro and in-vivo models, several groups have shown that the transforming properties of ALK fusions involve a plethora of alternative culprits capable of regulating intrinsic (i.e. cytoskeleton, cell growth etc.) and/or extrinsic (cell matrix invasion, tumour-host relationships etc.) pathways.
The identification of the driving lesion of ALCL will require the construction of international networks capable of synergizing their activities and constructing large and clinically annotated tissue libraries. The collection of viable tissues will facilitate the generation of batteries of 'patient derived tumourgrafts' (PDT).
The intracellular distribution of the fusions is due to the structure/function of ALK partners, resulting in either nuclear/cytoplasmic or cytoplasmic and in rare cases juxta-membranous localization. Virtually all partners (with the exclusion of MYH9-ALK) provide dimerization domains, leading to the homo/heterodimerization of the fusions and to the constitutive activation of the kinase [16, 17] . Conventional genomic approaches, and more recently next-generation sequencing (NGS), have shown alternative ALK translocations in many types of human cancers, including lung tumours [18, 19] .
ALCLs display additional alterations involving many chromosomes [8] [9] [10] 20] ; however, few recurrent somatic lesions have been reported. Two translocations were reported in ALK-ALCL, involving the DUSP22 gene, which is juxtaposed to the FRA7H fragile site, or to the gene coding for IRF4 [21] . Boi et al. [11] have recently shown that ALCLs display recurrent deletions affecting the 17p13.3-p12 region (25%), in which TP53 gene is located, and 6q21 (19%) encompassing PRDM1 and ATG5 genes. Finally, Vasmatzis et al. [22 && ] have recently described a set of genomic defects in diffuse large Bcell lymphoma and PTCL/ALCL encoding fusion proteins homologous to DNp63, a dominant-negative p63 isoform that inhibits the p53 pathway.
ALK chimeras were originally proven to be oncogenic in vivo [23] and these data were then confirmed in in-vitro models [24] and in genetically modified animals [25, 26] . Understanding how ALK signals act and defining the mechanisms responsible for its deregulation are critical for dissecting the mechanisms that mediate ALK cellular transformation and provide the basis for rational therapeutic approaches. By a large array of methods, it is now known that ALK fusions, and in particular the NPM-ALK chimera, interact with a plethora of molecules and elicit many pathways. These include the RAS/Erk, PLC-g, PI3K and Jak/signal transducers and activators of transcription (STAT), capable of controlling, individually or in association, cell proliferation, survival and cytoskeletal properties [19] .
The activation of the RAS/Erk pathway provides positive signals regulating cell growth and the inhibition of MEK (AZD6244 or shRNA) leads to cell cycle arrest, without significant changes in cell viability in ALKþ ALCL cells (R. Crescenzo, personal communication). Similarly, NPM-ALK can downmodulate, via PI3K-AKT, the inhibitory action of FOXO3a, upregulating cyclin D2 and downregulating p27, and providing positive growth signals.
We and other groups have shown that the neoplastic phenotype of NPM-ALK is largely mediated by STAT3. This induces the transcription of a large number of genes (coding and noncoding), promoting cell growth and survival. In shRNA-based repression experiments, Piva et al. have demonstrated that several genes are directly regulated by STAT3, and display canonical STAT3-binding sites within their regulatory regions, including CD30, GZMB, PRF1, IL1RAP and IL2RA (R. Piva, personal communication). From a diagnostic point of view, CD30, GZMB and PRF1 are known to be preferentially expressed by ALCL cells, and are commonly used in algorithms encompassing the differential diagnosis of different PTCL entities. Their transcription requires phosphorylated STAT3 complexes, which often include CCAAT/enhancer-binding protein beta (CEBPb) and activator protein 1 (AP-1) transcription factors. Notably AP-1 members play an important role in ALK-mediated transformation, controlling tumour growth and positive host signals, via platelet-derived growth factor [27 & ] (Fig. 1) . Interestingly, Zhang et al. [28] have recently reported that STAT3, engaging the interleukin (IL)-2Rg promoter, enhances the binding of DNA methyltransferases (DNMTs), leading ultimately to the transcriptional repression of IL-2Rg gene. The knockdown of IL-2Rg expression contributes to the neoplastic phenotype, as demonstrated by its forced expression that leads to the loss of NPM-ALK protein expression, and then apoptosis [28] . Ultimately, STAT3 downregulates T-cell associated molecules controlling T-cell identity of ALCL cells. In this context, NPM-ALK provides signals capable of bypassing T-cell receptor (TCR)-mediated activation [29, 30] (Fig. 1) .
Zhang et al. [31] have also elucidated additional features of STAT3, demonstrating STAT3-positive regulation of inducible T-cell costimulator (ICOS). The same group had previously shown that programmed cell death 1 ligand 1 (PDL-1) expression is also regulated by STAT3 [32] . Collectively, these data demonstrate that ALCL cells engage ICOS to gain a growth advantage, and an immunosuppressive cell surface protein, that is PDL-1, capable of downregulating host T-cell responses, as a novel mechanism of tumour escape. The overexpression of IL-21 [33] and deregulation of tumour necrosis factor (TNF)/Fas/TNF [34] can also contribute to ALK tumourigenic phenotype, favouring the survival of ALCL cells and overcoming host defences. Finally, ALK signalling controls hypoxia-inducible factor 1 alpha, a factor that directly controls neo-angiogenesis and provides a positive growth advantage to the lymphoma cells [35, 36] (Fig. 1) .
STAT3 can similarly upregulate the expression of several microRNA (miRNA) clusters (E. Spaccarotella, personal communication) including the miRNA17-92 [37] , known to have a role in human cancers. In ALCL, the miRNA17-92 overexpression overcomes in part the loss of STAT3 in an shRNA STAT3-inducible ALKþ ALCL model. More importantly, primary ALKþ ALCL displays higher miRNA17-92 levels [37] than ALKÀ ALCL and cutaneous T-cell lymphoma, and the usage of STAT3 inhibitors leading to the downregulation of this cluster could represent an attractive strategy for the treatment of ALCL lymphoma (C. Lin, personal communication).
The ability to successfully migrate and invade distant tissues contributes to the neoplastic phenotype, impairing clinical responses and long remissions. ALK signalling can efficiently module the cytoskeleton and promote invasion. The data reported by Ambrogio et al. [38] have recently been confirmed [39] . Dupuis-Coronas et al. [40] have shown that ALK, modulating the activity of finger-containing phosphoinositide kinase, enhances the invasive capacities of NPM-ALK cells and their capacity to degrade the extracellular matrix. Invasion of ALKþ ALCL cells is also modulated by the axis ALK-STAT3-Twist1 [41] (Fig. 1) .
In conclusion, it is evident that the tumourigenic properties of ALK signalling are more complex than originally proposed, confirming that ALK is a powerful kinase capable of providing a complete and broad oncogenic addiction. These properties make ALK an excellent therapeutic target.
ALKR AND ALKS ANAPLASTIC LARGE CELL LYMPHOMAS: TWO SIDES OF THE SAME COIN?
The debate on distinct entities among PTCLs remains open. Novel hypotheses are emerging on the origin and relationship of different PTCL entities. The concept that ALKÀ ALCL should be lumped within PTCL-NOS has been recently sponsored. Alternatively, a scenario in which all ALCLs can be incorporated in a single group, irrespective of ALK chimera, has been proposed. This level of uncertainty is corroborated by the fact that, once ALCL patients are stratified by stage, International Prognostic Index and so on, either groups display similar characteristics. In this landscape, CD30þ PTCLs represent a puzzling/confounding group [42] . Their precise definition is critical and sometime questionable. Immunophenotypically, they express weak/ partial CD30, with few cases coexpressing the CD15 antigen [43, 44] . Cytologically they display a certain monomorphism and they often have a functional TCR signalling (NFATc positive et cetera) [45,46 && ]. Clinically, CD30þ PTCLs share a more aggressive clinical course, justifying their distinction and a closer relationship to PTCL-NOS. We strongly believe that these uncertainties will be solved only when distinct molecular defects are discovered in different PTCLs.
Another similarly confusing topic considers the origin of ALCLs, and their putative normal counterpart elements. Several hypotheses have been proposed, taking into account their expression profile and a unique immune phenotype. The expression of perforin, TIA-1 and granzyme has been interpreted as a specific fingerprint, supporting the idea that ALCL may derive from cytotoxic T-lymphocytes. Alternatively, we speculate that the phenotype of ALCL may rather be the result of the deregulated expression of unique pathways and/or specific defects, which impose unique/fixed profiles. It is known that transcription factors can play a critical role in T-cell differentiation and once constitutively activated can undermine physiological programmes and reroute their development. On the basis of this assumption, we could speculate that the constitutive activation of STAT3 via ALK signalling might be responsible for the T-cell cytotoxic phenotype of ALKþ ALCL cells (i.e. TIA-1, GZMB, PRF1), even in cells that were committed to different lineages and/ or function (Fig. 2) . This leaves the open question as to why ALKÀ ALCL cases have a cytotoxic phenotype. To solve this question, we have analysed a large cohort of ALCL samples and found that a subset of ALKÀ ALCL clearly shares a STAT3 expression profile and detectable nuclear pSTAT3. Moreover, both ALKþ and ALKÀ ALCL reveal signatures, linked to the activation of c-MYC, NOTCH-1, or NFkB, and RAS/ERK, suggesting the existence of upstream activators. Interestingly, as several ALCL coshare overlapping signatures, ALCL may be driven by several activating defects or by a few lesions, such as ALK fusions, able to fire multiple signalling pathways. Search of ALCL pathogenetic lesions is under evaluation and it is predicted that new information will be available soon (Fig. 2) .
CAN WE USE PRECISION MEDICINE DATA TO IMPROVE EFFICACY?
The definitive molecular fingerprinting of neoplasms is now possible through the implementation of novel technologies such as NGS. Several NGS platforms are currently entering the clinical arena and it is plausible that, once there are interconnected and clinical-based networks of laboratories, many patients will have individualized molecular identikits. Nonetheless, caveats on the tumourigenic contribution of individual lesions and their functional role in the maintenance of the neoplastic phenotypes remain ambiguous. This critical issue should be added to the overwhelming capacity of tumour cells to adapt rapidly to the environment and to the stress imposed by drugs and host changes. Thus, the search for the 'magic bullet' may fail. Instead, the association of multiple 'smart' compounds could provide higher response rates and overcome resistance. As the cost for a novel drug is around one billion dollars and requires approximately 12-15 years, we need to overcome impairing inefficiencies. Many improvements in discovery programmes need to be rapidly put in place, addressing company inefficiencies (structural and operation), selection of viable targets, definition of good therapeutic biopredictors, innovative technologies, more efficient and reliable screening tests and faster and less expensive clinical tracks in molecularly defined and/or naive patients.
Although pharmaceutical companies are updating their pipelines, only a small number of drugs are successfully introduced into clinics. Hence, it is imperative to update our preclinical models, which are currently heavily dependent on in-vitro models and cell line xenograft mouse platforms. Indeed, the most frequently used cell lines poorly represent human tumours [47] . This has encouraged many institutions and the drug industry to perform their discovery programmes in a very large library of cell lines and correlate their drug responses with their molecular fingerprints characterized by multiple high-throughput platforms (NSG, phosphomapping and so on). The hope is to define better criteria and relationships between the genome and responses to therapies. We believe that this will improve our prediction and the selection of more reliable clinical responses, dissecting responders and refractory patients. But cell lines lack the host and its regulatory networks, have undergone extensive in-vitro selections and do not represent tumour heterogeneity.
The implantation of fresh primary neoplasms in several immunocompromised mice may solve some of these issues [48] . The generation of such individualized cancer models represents an unprecedented opportunity to test a battery of drugs for each individual patient and develop personalized oncology programmes. However, these strategies need to be linked to defined genetic defects. The combination of in-depth genetic and molecular profiling with innovative experimental models is the most likely manner through which we will be able to deliver lists of high-confidence, targetable lesions. Once validated in animals, these targets should provide more specific guidance on therapeutic targeting strategies. As the engraftment and growth of fresh tumour implants may require long periods of time, new technologies interrogating the functional networks of cancer cells and the impact and efficacy of libraries of specific inhibitors in vitro may provide alternative routes for the accelerated translation of novel modalities to clinical trials. Our group has recently embarked on such a programme and generated a battery of ALCL 'patient derived tumourgrafts' (PDT) [49] . These retain the immunophenotypic, genomic features of their corresponding primary tumours and display responses to conventional and innovative protocols that closely mimic those seen in donor patients. Their molecular characterization has demonstrated the presence of unique genomic defects and allowed us to discover new pathogenetic translocations and activating somatic mutations. The definition of a molecular identikit in PDTs will provide not only patients' fingerprints but also models to test the efficacy of selected drugs targeting hypothetical tumourigenic defects in each patient in vivo.
CONCLUSION
Little is yet known of mechanisms leading to T-cell lymphomagenesis. Nonetheless, the systematic usage of high throughput platforms has recently demonstrated that recurrent defects may be present in specific subsets of PTCLs. Although ALKþ ALCL and ALKÀ ALCL display heterogeneous complex karyotypes, they share common expression signatures and dysregulated signalling pathways. The use of NGS approaches will be instrumental for the more complete discovery of mechanisms driving the pathogenesis of ALCL. New molecular lesions, even in small subgroups of patients, will provide objective diagnostic criteria and the bases for 'intelligent' therapies, to be first validated in the most informative preclinical models (i.e. PDT and so on)
